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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
reslizumab is effective in improving quality of life and asthma control in adolescent and adult
patients with poorly controlled eosinophilic asthma.
STUDY DESIGN: This is a systematic review of three randomized controlled trials, published in
peer-reviewed journals from 2015 and 2016.
DATA SOURCES: Three randomized, placebo-controlled, double-blind clinical trials comparing
the effectiveness of reslizumab to a placebo in improving quality of life and asthma control.
Articles were found using CINAL and PubMed databases.
OUTCOMES MEASURED: Outcomes measured include quality of life, assessed using the
Asthma Quality of Life Questionnaire (AQLQ), and asthma control, assessed using the Asthma
Control Questionnaire-7 (ACQ-7).
RESULTS: Bjermer et al. and Castro et al. showed significant improvement in quality of life in
patients who received reslizumab compared to placebo. In Bjermer et al., 64% of patients
receiving reslizumab achieved an improvement in their AQLQ score, compared to 48% for those
receiving a placebo (p=0.0189). In Castro et al., 74% of patients receiving reslizumab had an
improvement in their AQLQ score, compared to 65% of those receiving a placebo (p=0.03).
Corren et al. showed a significant improvement in asthma control, with 71% of patients receiving
reslizumab having improvement, compared to 57% of patients in the control group (p=0.01).
CONCLUSION: Reslizumab is an effective treatment to improve quality of life and asthma
control in patients with inadequately controlled eosinophilic asthma.
KEY WORDS: Reslizumab, asthma
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INTRODUCTION
Asthma is a chronic inflammatory disease of the airways that is characterized by
reversible obstruction, airway inflammation, bronchial hyperreactivity, and airway narrowing.
Asthma is a common respiratory disease, affecting approximately 7.8% of the United States’
population.1 About 10% of these individuals have poorly controlled asthma. 2 An estimated $56
billion are spent annually for asthmatic patients.3 It is important to note that the subgroup of
patients with poorly controlled asthma disproportionately contributes to these costs, likely due to
increased exacerbations and hospitalizations. According to the CDC, the percentage of physician
office visits for patients with asthma is 6.3% annually.4 The primary diagnosis of asthma
accounts for an estimated two million emergency department visits annually.4
It is known that asthma is caused by inflammation of the airways due to the infiltration of
eosinophils, neutrophils, and T lymphocytes. This inflammation leads to airway edema and
bronchial hyperreactivity that activates the immune system. Together, this leads to
bronchoconstriction and limitation of airflow. There is a subgroup of asthmatic patients with an
eosinophil-predominant inflammatory infiltrate in the airways and increased blood and sputum
eosinophil levels.5 This subgroup is associated with poor treatment outcomes and increased risk
of exacerbations.6 Eosinophils are regulated by interleukin-5 (IL-5) and require its signaling for
growth and survival.5 This makes IL-5 inhibition a possible target for the treatment of
eosinophilic asthma.
Patients with asthma typically present with wheezing, dyspnea, cough, and other
respiratory symptoms. A patient’s daily activity and quality of life may be limited depending on
symptom severity. Standard treatments for asthma include short-acting agents that quickly treat
airway narrowing, and long-term controller medications that aim to reduce airway inflammation.
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Short-acting agents include inhaled short-acting beta-agonists (SABAs), such as albuterol, that
work to cause bronchodilation and reverse airflow limitation. SABAs are required for all
asthmatic patients for the immediate treatment of symptoms. Long-term controller medications
include inhaled corticosteroids (ICS), long-acting beta-agonists, and leukotriene modifiers. Daily
ICS therapy is currently the treatment of choice for persistent asthma. Systemic corticosteroids,
supplemental oxygen, and other medications may be used in acute exacerbations.
All of the medications previously listed are effective for managing symptoms or
controlling asthma. However, they are not enough in cases of asthma with poor control, such as
in the eosinophilic subgroup. Reslizumab (Cinqair) is a monoclonal antibody against IL-5 that
has been approved by the FDA as an add-on therapy for poorly controlled eosinophilic asthma.
By targeting IL-5, it works to decrease the number of eosinophils that cause airway
inflammation. Therefore, the medication aims to improve asthma control and quality of life by
targeting inflammation.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not reslizumab is
effective in improving quality of life and asthma control in adolescent and adult patients with
poorly controlled eosinophilic asthma.

METHODS
Several criteria were used to search for and select studies for this EBM review. Each
study included participants 12 years of age and older with inadequately controlled eosinophilic
asthma. In each study, the intervention was a reslizumab 3.0 mg/kg infusion. Comparisons were
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made between an experimental group receiving reslizumab infusions and a control group
receiving a placebo infusion. Outcomes measured included quality of life and asthma control.
Types of studies included in this selective EBM review include three randomized, placebocontrolled, double-blind clinical trials.
Articles were found using CINAL and PubMed databases, searching with key words
“reslizumab and asthma.” The selected articles were published in the English language in peer
reviewed journals from 2015-2016. Articles were chosen based on their relevance to the clinical
question and if they included patient oriented outcomes. Inclusion criteria were randomized,
placebo-controlled, double-blind clinical trials. Exclusion criteria were patients under the age of
12 years old or who had well controlled asthma. Statistics reported in this review include relative
benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), and pvalues. Table 1 demonstrates the demographics and characteristics of each study.
Table 1: Demographics & Characteristics of included studies
Study
Type
#
Age
Inclusion
Exclusion Criteria W/D Intervention
Pts (years)
Criteria
Bjermer5 Double- 315 12-75 -ACQ-7 score -Confounding lung
50
Reslizumab
(2016)
blind,
infusion 3.0
 1.5. -Airway disorders/pulmonary
placebomg/kg q 4
reversibility of conditions.
controlled
-Hypereosinophilic
weeks x 16
12% or more
RCT
syndrome.
weeks
after SABA
administration. -Use of systemic
corticosteroids 30
-Blood
days prior to
eosinophil
screening.
count of
-Current smoker.
400/L.
-Use of systemic
-Receiving at
immunosuppressive
least a
or
medium dose
ICS daily with immunomodulating
agents in the past 6
or without
months prior to
another
screening.
controller
- Other clinically
drug.
relevant
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Castro6
(2015)

Double- 489
blind,
placebocontrolled
RCT

12-75

Corren8
(2016)

Double- 496
blind,
placebocontrolled
RCT

18-65

-Same
inclusion
criteria as
Bjermer
(2016) in
addition to the
following:
-At least one
asthma
exacerbation 
3 days within
the past year
before
screening.
-Same
inclusion
criteria as
Bjermer
(2016)

comorbidities with
potential to interfere
with the study
schedule,
procedures, or
safety.
-Same exclusion
criteria as Bjermer
(2016) in addition to
the following:
-Females could not
be pregnant.
-Prior use of
reslizumab.
-Requirement for
treatment for an
asthma exacerbation
within 4 weeks of
screening period.
-Same exclusion
criteria as Bjermer
(2016)

4

56

Reslizumab
infusion 3.0
mg/kg q 4
weeks x 1
year

74

Reslizumab
infusion 3.0
mg/kg q 4
weeks x 16
weeks

OUTCOMES MEASURED
Outcomes measured included quality of life and asthma control following the
intervention. Bjermer et al. and Castro et al. used the Asthma Quality of Life Questionnaire
(AQLQ) to assess quality of life in the participants at baseline and the end of the treatment
period, which was at weeks 16 and 52, respectively.5-6 The AQLQ consists of 32 questions that
assess asthma symptoms, activity limitation, emotions, and environmental stimuli. 7 The
participants are asked to evaluate how each area has impacted them in the previous two weeks,
and rate each question on a 7-point scale; 1 meaning severely impaired, 7 meaning not impaired
at all.7 The score for the AQLQ is an average of all of the responses. The creators of the AQLQ
state that an improvement in the baseline score of  0.5 is the minimally important difference
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(MID) that has clinical significance, because this improvement can warrant a change in a
patient’s treatment plan.7 Both Bjermer et al. and Castro et al. used this MID, which allows for
dichotomous data. Both studies used a stratified Cochran-Mantel-Haenszel test to identify the
proportion of patients with a MID of  0.5-point improvement in their AQLQ score from
baseline.5-6
Corren et al. used the Asthma Control Questionnaire-7 (ACQ-7) to assess asthma control
at baseline and 16 weeks, the end of the treatment period. 8 The participant uses a 7-point scale to
answer questions related to night time awakenings, symptoms and severity, activity limitation,
and rescue inhaler use that have occurred within the previous week. 9 The scale ranges from 0
(totally controlled asthma) to 6 (severely uncontrolled). The ACQ-7 also includes a FEV
component measured by the researchers. The final ACQ-7 score is an average of all the
responses. Asthma is considered to be well controlled with a score <1.5.5 Similar to the AQLQ, a
change in baseline of  0.5-point decrease is the accepted MID for clinical significance.9 Corren
et al. used this MID, allowing for dichotomous data.

RESULTS
All three of the studies included in this review compared adolescent and adult patients in
an experimental group receiving a 3.0 mg/kg reslizumab infusion to a control group receiving a
placebo infusion. The intervention was studied as an adjuvant therapy for patients already taking
at least a medium-dose ICS with or without another controller medication. All patients had a
blood eosinophil count of  400/L. A full set of inclusion and exclusion criteria can be found in
Table 1 above. The first two studies assessed the efficacy of reslizumab in improving quality of
life, while the third study assessed the efficacy of the medication to improve asthma control.
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In the Bjermer et al. study, 315 patients were randomly allocated into experimental
(n=106) and control (n=105) groups. 265 patients completed the trial, with 88 in the
experimental group, and 85 in the placebo group. Another treatment group of 92 patients was
included in the study, but this group received a different dose of reslizumab and was therefore
excluded from this review. Patients were given an AQLQ at baseline and every 4 weeks until the
end of the treatment period at 16 weeks. This review will focus on the AQLQ changes from
baseline to week 16. Refer to Table 2 below for a summary of results from this study. Overall,
64% of patients receiving reslizumab achieved a MID of  0.5-point improvement in their
AQLQ score, compared to 48% for those receiving a placebo.5 This difference is statistically
significant, with a p-value of 0.0189. Determining the number needed to treat (NNT) value is
important to establish the clinical significance of the intervention. The NNT value in this study
was 7, meaning that for every 7 patients with inadequately controlled eosinophilic asthma treated
with reslizumab 3.0 mg/kg infusions every 4 weeks, 1 more patient will have an improvement in
their quality of life compared to those receiving placebo.
In the Castro et al. study, 489 patients were randomly assorted into experimental (n=245)
and control (n=244) groups. 433 patients completed the trial, with 218 in the reslizumab group
and 215 in the control group. It is important to note that this review focuses on the group of
patients who completed Study 1 in the Castro et al. article, as two different studies are reported.
Patients were given an AQLQ at baseline and weeks 16, 32, and 52. This review will focus on
changes in AQLQ scores from baseline to week 52 at the end of the trial. Refer to Table 2 below
for a summary of results from this study. A total of 74% of patients receiving reslizumab had a
MID of  0.5-point improvement in their AQLQ score, compared to 65% of those receiving a
placebo.6 This difference is statistically significant, with a p-value of 0.03. The NNT value in
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this study was 12, meaning that for every 12 patients with inadequately controlled eosinophilic
asthma treated with reslizumab 3.0 mg/kg infusions every 4 weeks, 1 more patient will have an
improvement in their quality of life compared to those receiving placebo.
Table 2: Comparison of improved AQLQ scores between reslizumab and placebo
Study
Control
Experiment
Relative
Absolute
Number
P value
event rate
event rate
benefit
benefit
needed to
(CER)
(EER)
increase
increase
treat
(RBI)
(ABI)
(NNT)
Bjermer
0.48
0.64
0.33
0.16
7
0.0189
et al.5
Castro et
0.65
0.74
0.14
0.09
12
0.03
al.6

In the Corren et al. study, 496 patients were randomized into experimental and control
groups, with 398 receiving reslizumab and 98 receiving placebo. At the end of the 16-week
treatment period, 422 patients completed the trial, with 340 enrolled in the experimental group
and 82 in the control group. ACQ-7 scores were compared from baseline and 16 weeks. Refer to
Table 3 below for a summary of results. 71% of patients receiving reslizumab had an
improvement in their asthma control with a  0.5-point decrease from baseline, compared to 57%
of patients in the control group.8 This difference is statistically significant, with a p-value of
0.01. The NNT value in this study was 8, meaning that for every 8 patients with poorly
controlled asthma treated with reslizumab 3.0 mg/kg infusions q 4 weeks, 1 more patient will
have an improvement in their asthma control compared to those receiving placebo.
Table 3: Comparison of improved ACQ-7 scores between reslizumab and placebo (Corren
et al.8)
Control
Experiment
Relative
Absolute
Number
P value
event rate
event rate
benefit
benefit
needed to
(CER)
(EER)
increase
increase
treat (NNT)
(RBI)
(ABI)
0.57
0.71
0.25
0.14
8
0.01
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DISCUSSION
Reslizumab was recently approved by the FDA as an adjunctive controller medication for
the management of inadequately controlled eosinophilic asthma. As mentioned previously, it was
studied in patients taking at least a medium-dose ICS with or without another controller
medication. It does not have any other treatment indications and should not be used for the
treatment of acute symptoms or asthma exacerbations. It is approved for a monthly intravenous
dosing of 3.0 mg/kg.10 Although this medication cannot be taken by the patient at home, it is still
feasible because they only have to get it once per month, and it only takes 20-50 minutes to
infuse.10 Adverse effects reported for reslizumab include headache, URI, nausea and vomiting,
allergic rhinitis, back pain, sinusitis, UTI, dyspnea, dizziness, and oropharyngeal pain. 10 It is
important to note that reslizumab has a Black Box warning for anaphylaxis. 10 The only
contraindication is an allergy to the medication.
The first two studies showed that those treated with reslizumab had significant
improvement in AQLQ scores, and the third study showed significant improvement in the ACQ7 score for those treated with reslizumab compared to placebo. The treatment effects of
reslizumab in improving quality of life and asthma control were large based on the small NNT
values listed above, considering this medication is an adjunctive therapy and the drug is
relatively tolerable. Since the treatment effects are large, reslizumab holds a justified clinical
importance as an adjuvant treatment for inadequately controlled eosinophilic asthma.
While data show that there was a statistically significant number of patients who had a
MID of  0.5-point decrease in their ACQ-7 score (i.e. improvement in asthma control), it is
possible that their asthma was still not controlled. Adequately controlled asthma correlates with
an ACQ-7 score of <1.5.5 It is possible that some patients, while achieving a MID in
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improvement, still had an ACQ-7 score 1.5 indicating they still had inadequately controlled
asthma after receiving reslizumab. While an improvement in their score is certainly a step in the
right direction, it may not be enough to justify the use of this medication to convert a patient’s
status to well controlled asthma. Since the clinical question posed in this review only investigates
an improvement in asthma control, this would be an area of interest for further study.
One limitation to the studies is the route of administration, but unfortunately this cannot
be avoided. Researchers discuss that receiving an IV infusion may cause patients to perceive
stronger treatment effects due to the route of administration, so this could have affected the
outcomes measured.6 However, the intervention was compared to a placebo infusion and had a
statistically significant difference in outcomes. Patient self-report and honesty on the AQLQ and
ACQ-7 could have affected outcomes as well. The questions covered a span of the previous 1 or
2 weeks, and patients may have an error in their memory that affected their responses and
therefore the outcomes measured. Another limitation explained by the original researchers is
that using a MID of  0.5-point improvement in AQLQ scores is not a valid measure to assess
outcomes for groups of patients when an adjuvant therapy is added to their current ICS regimen. 5
While not explicitly mentioned by Corren et al., the validity of the MID for the ACQ-7 score
may be questionable as well. Further studies are warranted to determine the validity of using a
MID for both the AQLQ and ACQ-7 when adding a therapy to an ICS regimen.

CONCLUSION
Reslizumab is an effective treatment to improve both quality of life and asthma control in
a subgroup of patients with poorly controlled eosinophilic asthma. Future study is warranted to
evaluate if a significant number of patients achieve a MID in improvement in their ACQ-7 score
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in addition to an ACQ-7 score of <1.5, indicating well controlled asthma. Reslizumab should not
be indicated as monotherapy in these patients, but considered as an add-on treatment in those
who are not well controlled with the use of a medium-dose ICS, as this was the population in
each study.
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